AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Profusa, Inc. Common Stock
XNAS · usd
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG011J0RMT6
0.84▼ 0.18 (-17.74%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
1.02
Day's Range
0.82 – 1.08
52-Week Range
0.05 – 28.32
Volume
1.1M
Avg Volume
5.1M
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2025-07-14
Share count as of August 18, 2026

Profusa, Inc. Common Stock (PFSA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Profusa, Inc. Common Stock (PFSA)
What is Profusa, Inc. Common Stock's Market Cap?
Profusa, Inc. Common Stock's Market Cap is $508.2K, based on as-reported figures from SEC (XBRL) filings.
What is Profusa, Inc. Common Stock's Revenue (TTM)?
Profusa, Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Profusa, Inc. Common Stock's Net Income (TTM)?
Profusa, Inc. Common Stock's Net Income (TTM) is -$35.8M, based on as-reported figures from SEC (XBRL) filings.
What is Profusa, Inc. Common Stock's Diluted EPS (TTM)?
Profusa, Inc. Common Stock's Diluted EPS (TTM) is -59.15, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PFSAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expenses)
Loss on change in the fair value of convertible notes——
Gain on change in fair value of warrant liabilities
Loss on disposal of digital assets—
Interest expense (including related parties amounts of $5 and $533 for the three months ended June 30, 2026 and 2025, and $10 and $1,142 for the six months ended June 30, 2026 and 2025, respectively)
Financing costs
Other income
Total other expense, net
Net loss
Net loss per share, basic (in Dollars per share)—
Net loss per share, diluted (in Dollars per share)—